Stock listing

Shanghai:688046 GemPharmatech Co., Ltd. (药康生物) 股价

Follow GemPharmatech Co., Ltd. into a list and get an email when it puts out news.

Share price · SSE:688046

¥26.88 CNY -3.03 (-10.1%)

Close on Nov 20, 2026

Past year +60.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥26.81 – ¥28.71 CNYNov 20, 2026
Volume
6.24M sharesNov 20, 2026
Market cap
¥11.03B CNYAt the close on Nov 20, 2026 · price × 410.2M shares outstanding
52-week range
¥12.89 – ¥43.47 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥339.9M CNYMedian day 9.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
GemPharmatech Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688046 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥26.88-3.03-10.1%¥28.11¥28.71¥26.816,240,804
¥29.91-2.29-7.1%¥32.22¥32.85¥29.515,792,049
¥32.20+0.81+2.6%¥31.60¥33.29¥31.115,688,651
¥31.39-1.08-3.3%¥31.67¥32.40¥31.013,541,442
¥32.47-2.03-5.9%¥34.05¥34.19¥32.006,219,451
¥34.50+0.60+1.8%¥33.98¥35.13¥33.116,606,035
¥33.90-0.010.0%¥33.90¥33.99¥32.446,315,059
¥33.91+0.35+1.0%¥34.51¥35.23¥33.266,199,830
¥33.56+0.86+2.6%¥32.80¥35.81¥32.807,073,229
¥32.70-0.65-1.9%¥31.01¥35.68¥31.0010,001,842
¥33.35+2.72+8.9%¥30.04¥33.69¥30.0312,229,270
¥30.63+3.48+12.8%¥27.25¥30.72¥26.539,879,199
¥27.15-2.64-8.9%¥29.23¥29.70¥26.7010,104,335
¥29.79+0.51+1.7%¥29.13¥30.25¥27.8010,402,066
¥29.28+0.60+2.1%¥28.48¥32.32¥26.6413,498,745
¥28.68-0.31-1.1%¥29.02¥29.98¥28.338,195,549
¥28.99+2.41+9.1%¥26.89¥29.62¥26.898,362,544
¥26.58-0.67-2.5%¥27.73¥27.82¥26.386,518,299
¥27.25-0.29-1.1%¥27.24¥27.84¥26.497,828,105
¥27.54-0.24-0.9%¥27.03¥27.87¥25.438,372,782
¥27.78-1.43-4.9%¥29.51¥29.88¥27.406,130,110
¥29.21-1.04-3.4%¥31.35¥31.35¥29.136,853,357
¥30.25+1.75+6.1%¥28.40¥30.67¥27.619,951,282
¥28.50-0.50-1.7%¥29.00¥29.76¥26.4212,639,663
¥29.00-2.70-8.5%¥32.32¥33.30¥28.6212,129,589
¥31.70-0.05-0.2%¥30.54¥33.85¥30.5410,624,369
¥31.75-0.97-3.0%¥32.95¥32.95¥31.737,372,695
¥32.72-0.94-2.8%¥32.80¥33.48¥30.0012,691,810
¥33.66-0.97-2.8%¥34.64¥35.95¥33.4410,346,975
¥34.63-0.87-2.5%¥35.23¥35.50¥32.908,833,429
¥35.50-2.44-6.4%¥36.97¥37.24¥35.1811,633,500
¥37.94+2.96+8.5%¥34.86¥38.78¥34.8316,589,266
¥34.98-0.08-0.2%¥34.73¥37.17¥34.739,101,558
¥35.06-0.86-2.4%¥35.99¥36.40¥34.957,640,264
¥35.92-2.69-7.0%¥38.54¥38.61¥35.8013,507,718
¥38.61+0.88+2.3%¥37.72¥40.30¥37.0812,226,088
¥37.73+0.95+2.6%¥35.85¥39.48¥35.8512,079,773
¥36.78+1.50+4.3%¥36.00¥37.45¥35.5012,473,420
¥35.28+0.73+2.1%¥34.91¥36.79¥34.3912,464,129
¥34.55+0.50+1.5%¥33.83¥36.55¥33.6012,956,946
¥34.05+1.68+5.2%¥32.21¥34.30¥31.9112,427,163
¥32.37-0.45-1.4%¥32.79¥33.35¥32.188,493,688
¥32.82+3.03+10.2%¥29.31¥33.29¥29.3113,776,660
¥29.79-0.78-2.6%¥30.57¥30.58¥28.917,859,626
¥30.57-1.05-3.3%¥31.34¥31.34¥30.047,449,418
¥31.62-0.86-2.6%¥32.29¥32.55¥31.079,655,570
¥32.48+1.26+4.0%¥31.31¥32.90¥30.6114,526,982
¥31.22+0.51+1.7%¥30.66¥31.22¥30.515,244,082
¥30.71-1.03-3.2%¥32.20¥32.20¥30.438,380,179
¥31.74+0.62+2.0%¥31.76¥31.85¥30.808,772,303
¥31.12-0.05-0.2%¥31.31¥31.95¥30.619,626,465
¥31.17-0.74-2.3%¥31.91¥31.97¥30.5010,486,621
¥31.91-0.59-1.8%¥31.50¥32.16¥31.218,728,657
¥32.50-0.87-2.6%¥33.01¥33.75¥31.8010,086,830
¥33.37+0.21+0.6%¥33.16¥33.57¥32.4010,011,380
¥33.16-1.33-3.9%¥34.83¥35.80¥32.5312,175,906
¥34.49+0.61+1.8%¥32.68¥35.05¥32.4017,083,578
¥33.88-0.47-1.4%¥35.04¥35.78¥32.8216,768,860
¥34.35-2.35-6.4%¥35.13¥35.80¥33.3623,446,175
¥36.70+0.70+1.9%¥37.55¥38.80¥35.2830,625,123
Ticker
Shanghai:688046
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All GemPharmatech Co., Ltd. news

GemPharmatech Co., Ltd. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
35 in the last 12 months · 57 in all · newest Nov 19, 2026 · oldest 2025

Valuation

P/E 54.4× against a median of 58.0×: 3rd lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥9.92B CNY
P/E
54.4×
EV/sales
10.5×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
4.7×
Gross margin
64.9%
Operating margin
26.3%
Net margin
21.5%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
GemPharmatech Co., Ltd. Class A · SSE:688046US$1.65BUS$1.49B54.4×10.5×n/a4.7×21.5%0.0×n/a
Azenta, Inc. · NASDAQ:AZTAUS$1.96BUS$1.63Bn/a2.6×n/a1.4×−26.9%0.0×1.59
Syngene International Ltd. · NSE:SYNGENEUS$1.96BUS$1.96B97.5×5.2×20.0×3.7×5.3%0.1×n/a
Cohance Lifesciences Ltd · NSE:COHANCEUS$1.91BUS$1.88B167×8.1×55.1×4.5×5.0%0.1×n/a
Alamar Biosciences, Inc. · NASDAQ:ALMRUS$1.84BUS$1.66Bn/a14.5×n/a6.1×−48.2%0.1×1.70
Fortrea Holdings Inc. · NASDAQ:FTREUS$1.79BUS$2.62Bn/a1.0×28.7×3.4×−2.6%2.0×1.68
ChemoMetec A/S · OMXCOP:CHEMMUS$1.72BUS$1.68B58.0×22.3×40.6×16.1×39.5%0.0×n/a
PolyPeptide Group AG · SIX:PPGNUS$1.62BUS$1.71Bn/a4.0×34.2×4.2×−5.4%0.4×n/a
Personalis, Inc. · NASDAQ:PSNLUS$1.55BUS$1.39Bn/a17.3×n/a7.3×−147.7%0.2×2.03
Sino Biological Inc. Class A · SZSE:301047US$1.45BUS$1.01B54.1×8.5×n/a1.9×22.6%0.0×n/a
Qingdao Haier Biomedical Co., Ltd. Class A · SSE:688139US$1.41BUS$1.16B34.7×3.1×n/a2.1×10.8%0.0×n/a
Median of the othersUS$1.75BUS$1.67B58.0×6.7×34.2×4.0×1.2%0.1×1.69

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
39.32 CNY · Analysts' mean
EPS, year to Dec 2026
0.49 · 2 analysts
Revenue, year to Dec 2026
964.2M · 2 analysts

Team and board

Officers

OfficerRole
Brandy WilkinsonChief Executive Officer

Board

DirectorRole
Xiang GaoChair of the Board

Events

QuarterResultsShare move
Q1 2023Apr 19, 2023 · Before open−1.1%
Q3 2022Oct 30, 2022 · After close+0.1%
Q2 2022Aug 19, 2022 · After close+4.7%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue793.4M686.8M622.2M516.5M393.8M261.9M192.7M
Cost of revenue284.4M261.1M201.5M147.8M101.1M73.2M63.9M
Gross profit509.0M425.8M420.7M368.7M292.7M188.7M128.8M
Research and development92.1M87.1M96.6M82.9M55.2M48.2M30.3M
Selling, general and administrative118.1M110.5M84.9M73.3M58.8M35.6M47.2M
Operating income182.0M122.3M166.3M171.6M150.6M97.7M49.6M
Depreciation and amortization88.2M84.8M53.7M39.1M28.8M16.8M7.43M
EBITDA270.2M207.2M220.1M210.7M179.4M114.5M57.1M
Interest expense6.08M4.30M2.76M495.5K744.9K724.0K255.1K
Income before tax164.9M119.2M161.3M173.7M143.3M91.4M46.9M
Net income142.6M109.8M158.9M164.7M124.9M76.4M34.7M
Earnings per share, basic0.350.270.390.400.300.210.10

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents486.6M701.4M560.2M421.7M293.5M524.2M221.9M
Short-term investments757.7M467.3M637.7M791.2M205.8M26.9M
Receivables385.0M350.8M269.4M185.2M118.6M90.7M63.5M
Inventory73.0M54.2M47.1M49.5M30.1M17.3M12.4M
Current assets1.75B1.71B1.66B1.47B706.9M647.2M329.0M
Total assets2.87B2.57B2.58B2.25B1.05B883.2M388.1M
Accounts payable68.1M72.2M101.9M50.8M61.7M46.3M23.2M
Current liabilities527.1M371.2M366.4M214.1M191.7M149.5M123.5M
Long-term debt20.0M
Total liabilities637.9M437.9M452.9M276.0M268.8M225.9M147.7M
Shareholders' equity2.23B2.13B2.12B1.98B785.6M657.2M240.5M
Shares outstanding410.0M410.0M410.0M410.0M410.0M360.0M360.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations227.0M90.3M116.6M106.0M113.3M129.8M65.1M
Capital spending-105.0M-113.7M-205.9M-190.3M-89.1M-167.1M-45.7M
Free cash flow122.0M-23.4M-89.3M-84.3M24.2M-37.3M19.5M
Dividends paid-61.2M-80.1M-17.9M-283.5K-680.0K-672.3K-235.8K
Change in cash-215.3M141.2M138.4M128.1M-230.7M302.3M198.7M

Open Financials

Filings

FilingDateTypeFiled with
(688046)"GEMPHARMATECH CO., LTD."Announcement on Departure of Key TechnicianNov 19, 2026Management or board changeShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Acquisition of 80% Equity Interest in Nanjing Bymybio Biotechnology Co., Ltd.Nov 17, 2026Acquisition or disposalShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Convening the Q3 2026 Performance BriefingOct 29, 2026Other filingsShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Report for Q3 2026Oct 29, 2026Quarterly reportShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Provision for Asset Impairment for the First Three Quarters of 2026Oct 29, 2026ResultsShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business LicenseOct 29, 2026Other filingsShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Expiration of the Lock-up Period and Satisfaction of Unlocking Conditions for the Reserved Grant under the 2025 Employee Stock Ownership PlanOct 29, 2026Operations updateShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Capital Increase in Wholly-owned SubsidiariesOct 29, 2026Other filingsShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Resolutions of the 2nd Meeting of the 3rd Board of DirectorsOct 29, 2026Meeting outcomeShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Appointment of Board SecretaryOct 20, 2026Management or board changeShanghai Stock Exchange
All 56 filings
FilingDateTypeFiled with
(688046)"GEMPHARMATECH CO., LTD."Announcement on Election of Employee Representative Director for the 3rd Board of DirectorsOct 20, 2026Management or board changeShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Completion of Election of New Board of Directors and Appointment of Senior Executives and Securities Affairs RepresentativesOct 20, 2026Other filingsShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Oct 20, 2026Meeting outcomeShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026Oct 16, 2026DividendShanghai Stock Exchange
(688046)"GEMPHARMATECH CO., LTD."Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTEROct 9, 2026Other filingsShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on Resolutions of the 21st Meeting of the 2nd Board of DirectorsSep 30, 2026Other filingsShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on the Opening of a Dedicated Settlement Account for Wealth Management Products Purchased with Raised FundsSep 23, 2026Other filingsShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Sep 10, 2026Meeting outcomeShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Indicative Announcement on the Report on Results of Shareholders' Inquiry-Based Transfer and Changes in Equity Interests of Shareholders Holding More Than 5% of Shares Reaching an Integral Multiple of 5%Sep 2, 2026Ownership change noticeShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Indicative Announcement on the Pricing of the Shareholder's Inquiry-based TransferAug 25, 2026Other filingsShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Shareholder Inquiry Transfer PlanAug 24, 2026Acquisition or disposalShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on the Profit Distribution Proposal for the First Half of 2026Aug 19, 2026DividendShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on Abnormal Fluctuations in Stock TradingAug 10, 2026Explanation requestShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on the Vesting Results of the Third Vesting Period of the Initial Grant under the 2022 Restricted Share Incentive Plan and the Listing of the SharesJul 29, 2026ResultsShanghai Stock Exchange
"GEMPHARMATECH CO., LTD."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026Jul 21, 2026GuidanceShanghai Stock Exchange
Announcement on Capital Increase in Joint-stock Company and Related Party TransactionsJun 18, 2026Other filingsShanghai Stock Exchange
Announcement on Expiration of the Lock-up Period and Achievements of Unlocking Conditions for the Initial Grant Part of 2025 Employee Stock Ownership PlanJun 5, 2026Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2025Jun 2, 2026DividendShanghai Stock Exchange
Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026May 22, 2026Meeting noticeShanghai Stock Exchange
Announcement on Resolutions of the 2025 Annual General MeetingMay 14, 2026Meeting noticeShanghai Stock Exchange
Announcement on Canceling Stock Appreciation Right under 2025 Stock Appreciation Right Incentive PlanMay 13, 2026Other filingsShanghai Stock Exchange
Announcement on Adding Partial Internal Corporate Governance SystemsApr 22, 2026Other filingsShanghai Stock Exchange
Announcement on Using Idle Self-owned Funds for Entrusted Wealth ManagementApr 3, 2026Other filingsShanghai Stock Exchange
Announcement on Preliminary Earnings Estimate for 2025Feb 3, 2026Other filingsShanghai Stock Exchange
Announcement on Share Repurchase by Joint-stock Company and Related Party TransactionsJan 7, 2026Acquisition or disposalShanghai Stock Exchange
Announcement on Implementation of Semi-annual Dividend Distribution for 2025Nov 13, 2025DividendShanghai Stock Exchange
Announcement on Implementation Result of Shares Repurchase and Share ChangesOct 29, 2025Other filingsShanghai Stock Exchange
Announcement on Completion of Non-trading Transfer of Reserved Shares under the 2025 Employee Stock Ownership PlanOct 27, 2025Operations updateShanghai Stock Exchange
Announcement on Electing Employee Representative Director of the 2nd Board of DirectorsOct 13, 2025Management or board changeShanghai Stock Exchange
Announcement on Progress in Repurchasing Shares through Call AuctionOct 9, 2025Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 1st Holders' Meeting for 2025 Employee Stock Ownership PlanSep 29, 2025Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025Sep 25, 2025Meeting noticeShanghai Stock Exchange
Announcement on Cancelling Board of Supervisors, Amending the Articles of Association, Handling Industrial and Commercial Change Registration, and Revising and Formulating Some Corporate Governance SystemsAug 22, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2024Jul 4, 2025DividendShanghai Stock Exchange
Announcement on Change of Sponsor Representative for Continuous SupervisionJun 30, 2025Other filingsShanghai Stock Exchange
Announcement on Cancellation and Opening of Special Settlement Accounts for Raised Fund Financial ProductsJun 25, 2025Other filingsShanghai Stock Exchange
Announcement on Adjusting Total Cash Dividends for 2024 Annual Profit DistributionJun 6, 2025DividendShanghai Stock Exchange
Announcement on Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement for Raised FundsJun 5, 2025Other filingsShanghai Stock Exchange
Announcement on Resolution of the 2024 Annual General MeetingMay 28, 2025Meeting noticeShanghai Stock Exchange
Announcement on Granting Stock Appreciation Rights to Incentive Objects of 2025 Stock Appreciation Right Incentive PlanMay 23, 2025Other filingsShanghai Stock Exchange
Announcement on Convening the 2024 Annual and Q1 2025 Performance and Cash Dividend BriefingMay 19, 2025DividendShanghai Stock Exchange
Announcement on the Remuneration Plan for Directors, Supervisors, and Senior Management Members in 2025Apr 25, 2025Other filingsShanghai Stock Exchange
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025Apr 21, 2025Meeting noticeShanghai Stock Exchange
Announcement on Listing and Circulation of Some Restricted Stocks in Initial Public OfferingApr 16, 2025Other filingsShanghai Stock Exchange
Announcement on Adding Extraordinary Proposal to the 1st Extraordinary General Meeting in 2025Apr 8, 2025Meeting noticeShanghai Stock Exchange
Announcement on Resolution of the 8th Meeting of the 2nd Board of SupervisorsMar 24, 2025Other filingsShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from GemPharmatech Co., Ltd. Class A’s releases

Common shares
410,186,200
Fully diluted
410,186,200

Fully diluted

LineShares
Common shares410,186,200

Share count over time

CountShares
Nov 22, 2026410,186,200

Open Cap table

Shareholders

HolderSharesValueAs of
Acadian Emerging Markets Portfolio433KUS$1.55MJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF219KUS$780KJun 30, 2026
Strategic Advisers Emerging Markets Fund185KUS$531KMay 31, 2026
Emerging Markets Core Equity 2 Portfolio155KUS$555KJul 31, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF51,444US$183KJun 30, 2026
The Emerging Markets Small Cap Series37,823US$135KJul 31, 2026
Dimensional Emerging Core Equity Market ETF26,751US$95,661Jul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF22,008US$78,700Jul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF12,740US$45,558Jul 31, 2026
Emerging Markets Social Core Equity Portfolio10,762US$38,526Jul 31, 2026
All 12 holders
HolderSharesValueAs of
World ex U.S. Core Equity Portfolio8,927US$31,957Jul 31, 2026
Siit World Equity Ex-Us Fund8,245US$23,624May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brandy WilkinsonChief Executive Officer · Since at least Oct 22, 2025
Xiang GaoChair of the Board · Since at least Oct 22, 2025

Open People

Log in to ask 6ix AI your own questions about GemPharmatech Co., Ltd.